Pfizer has granted exclusive development and marketing rights to ChemRar group company SatRx for their DPP(1)-IVi compound, PF-00734200 for type 2 diabetes (T2D). T2D is one of the most burdensome chronic non-communicable diseases, which ...
Tags: Satrx Exclusive License, epidemic proportions, R&D portfolio